A Comparison of Planned Dose in TBI VMAT Treatment with Dosimetry Using Portal Dosimetry® and IBA MatriXX®

Bone Marrow Transplant (BMT) is an essential therapeutic intervention in the treatment of diseases such as leukemia and lymphoma, where Total Body Irradiation (TBI) plays a crucial role by eradicating residual diseases and inducing immunosuppression, thus facilitating cell transplantation and reducing the risk of graft rejection. Traditionally, TBI has used large radiation fields, which can lead to significant toxicities in organs at risk (OARs) due to challenges in dose optimization. Volumetric Modulated Arc Therapy (VMAT) emerges as a promising technique, offering advantages such as the use of smaller treatment spaces and reduced doses to OARs, which may improve patient quality of life and reduce treatment costs. This study evaluates the effectiveness of VMAT in TBI by comparing the planned dose with the dose measured by quality control systems, such as the MatriXX FFF from IBA and the Portal Dosimetry from the VitalBeam linear accelerator, demonstrating that VMAT is a viable and effective alternative with the potential to optimize therapeutic outcomes in BMT.